Evidence map›Paper›PMID 33835346›Full record

ArticleGlycoconjugate journal2021

Increased ERK phosphorylation and caveolin-1 expression on K562 human chronic myelogenous leukemia cells by jacalin, a dietary plant lectin.

Lavanya V, Shazia Jamal, Neesar Ahmed

Abstract read
PubMed Publisher
In one paragraph

Article in Glycoconjugate journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Lavanya VSchool of Life Sciences, B S A Crescent Institute of Science and Technology, Vandalur, Chennai, Tamil Nadu, 600048, India.
Shazia JamalSchool of Life Sciences, B S A Crescent Institute of Science and Technology, Vandalur, Chennai, Tamil Nadu, 600048, India.
Neesar AhmedSchool of Life Sciences, B S A Crescent Institute of Science and Technology, Vandalur, Chennai, Tamil Nadu, 600048, India. neesar.sls@crescent.education.ORCID 0000-0002-7367-2188

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The potential antitumor effects of jacalin, the plant lectin that specifically recognizes the tumor-associated Thomsen-Friedenreich antigen has been extensively studied. We had earlier reported jacalin to be mitogenic to K562, the Bcr-Abl expressing erythroleukemia cell line. The dearth of studies highlighting the proliferative effects of jacalin and other lectins motivated us to unveil the mechanism underlying the mitogenic effects of jacalin. Caveolin-1 (cav-1) is an integral membrane protein, known to play a crucial role in cell signaling, lipid transport, and membrane trafficking. The role of cav-1 in tumorigenesis is considered to be controversial as it can suppress as well as promote tumor growth, depending on the cellular context. In the present study, we propose that cav-1 plays the central role in the mitogenic effects of jacalin on the K562 cells. In accordance, the mRNA, as well as protein expression of cav-1 was found to be upregulated in the jacalin-treated K562 cells as compared to the untreated control. Further, jacalin stimulation also increased the phosphorylation of ERK and Akt. The rationale that leads to the initial conjecture about cav-1 was that the sequence of jacalin possesses a cav-1-binding site.

Indexed as

Antineoplastic Agents, PhytogenicCaveolin 1Extracellular Signal-Regulated MAP KinasesGene Expression RegulationHumansK562 CellsLeukemia, MyeloidPhosphorylationPlant LectinsAntineoplastic Agents, PhytogenicCAV1 protein, humanCaveolin 1Extracellular Signal-Regulated MAP KinasesjacalinPlant LectinsCaveolin-1JacalinK562 cellsPP2A

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.